Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes.

Yao CY, Chen CH, Huang HH, Hou HA, Lin CC, Tseng MH, Kao CJ, Lu TP, Chou WC, Tien HF.

Blood Adv. 2017 Aug 16;1(19):1505-1516. doi: 10.1182/bloodadvances.2017008284. eCollection 2017 Aug 22.

2.

The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model.

Hsu YC, Chiu YC, Lin CC, Kuo YY, Hou HA, Tzeng YS, Kao CJ, Chuang PH, Tseng MH, Hsiao TH, Chou WC, Tien HF.

J Hematol Oncol. 2017 Jul 11;10(1):139. doi: 10.1186/s13045-017-0508-x.

3.

The 1-Tosylpentan-3-one Protects against 6-Hydroxydopamine-Induced Neurotoxicity.

Kao CJ, Chen WF, Guo BL, Feng CW, Hung HC, Yang WY, Sung CS, Tsui KH, Chu H, Chen NF, Wen ZH.

Int J Mol Sci. 2017 May 19;18(5). pii: E1096. doi: 10.3390/ijms18051096.

4.

Higher HOPX expression is associated with distinct clinical and biological features and predicts poor prognosis in de novo acute myeloid leukemia.

Lin CC, Hsu YC, Li YH, Kuo YY, Hou HA, Lan KH, Chen TC, Tzeng YS, Kuo YY, Kao CJ, Chuang PH, Tseng MH, Chiu YC, Chou WC, Tien HF.

Haematologica. 2017 Jun;102(6):1044-1053. doi: 10.3324/haematol.2016.161257. Epub 2017 Mar 24.

5.

Repurposing ospemifene for potentiating an antigen-specific immune response.

Kao CJ, Wurz GT, Lin YC, Vang DP, Phong B, DeGregorio MW.

Menopause. 2017 Apr;24(4):437-451. doi: 10.1097/GME.0000000000000776.

6.

High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both In Vivo and In Vitro.

Wang F, Chang JT, Kao CJ, Huang RS.

Mol Cancer Ther. 2016 May;15(5):1123-31. doi: 10.1158/1535-7163.MCT-15-0943. Epub 2016 Feb 12.

7.

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.

Wurz GT, Kao CJ, DeGregorio MW.

Ther Adv Med Oncol. 2016 Jan;8(1):4-31. doi: 10.1177/1758834015615514. Review.

8.

Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice.

Kao CJ, Wurz GT, Lin YC, Vang DP, Griffey SM, Wolf M, DeGregorio MW.

Cancer Immunol Res. 2015 Jul;3(7):741-50. doi: 10.1158/2326-6066.CIR-14-0234. Epub 2015 Feb 11.

9.

Tecemotide: an antigen-specific cancer immunotherapy.

Wurz GT, Kao CJ, Wolf M, DeGregorio MW.

Hum Vaccin Immunother. 2014;10(11):3383-93. doi: 10.4161/hv.29836. Review.

10.

Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.

Wurz GT, Kao CJ, DeGregorio MW.

Clin Interv Aging. 2014 Nov 13;9:1939-50. doi: 10.2147/CIA.S73753. eCollection 2014. Review.

11.

Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model.

Kao CJ, Wurz GT, Monjazeb AM, Vang DP, Cadman TB, Griffey SM, Wolf M, DeGregorio MW.

Cancer Immunol Res. 2014 Jun;2(6):581-9. doi: 10.1158/2326-6066.CIR-13-0205. Epub 2014 Mar 10.

12.

Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.

Kao CJ, Wurz GT, Schröder A, Wolf M, Degregorio MW.

Oncoimmunology. 2013 Oct 1;2(10):e26285. Epub 2013 Sep 12.

13.

Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy development.

Vang DP, Wurz GT, Griffey SM, Kao CJ, Gutierrez AM, Hanson GK, Wolf M, DeGregorio MW.

J Vis Exp. 2013 Oct 30;(80):e50868. doi: 10.3791/50868.

14.

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.

Soe LH, Wurz GT, Kao CJ, Degregorio MW.

Int J Womens Health. 2013 Sep 25;5:605-11. doi: 10.2147/IJWH.S39146. Review.

15.

miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.

Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, deVere White RW, Kung HJ.

Oncogene. 2014 May 8;33(19):2495-503. doi: 10.1038/onc.2013.200. Epub 2013 Jun 3.

16.

Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.

Wurz GT, Gutierrez AM, Greenberg BE, Vang DP, Griffey SM, Kao CJ, Wolf M, DeGregorio MW.

J Transl Med. 2013 Mar 13;11:64. doi: 10.1186/1479-5876-11-64.

17.

Cross-cultural effect on suboptimal effort detection: an example of the Digit Span subtest of the WAIS-III in Taiwan.

Yang CC, Kao CJ, Cheng TW, Yang CC, Wang WH, Yu RL, Hsu YH, Hua MS.

Arch Clin Neuropsychol. 2012 Dec;27(8):869-78. doi: 10.1093/arclin/acs081. Epub 2012 Sep 27.

PMID:
23018018
18.

In-situ template synthesis of a polymer/semiconductor nanohybrid using amphiphilic conducting block copolymers.

Lee YH, Chang CJ, Kao CJ, Dai CA.

Langmuir. 2010 Mar 16;26(6):4196-206. doi: 10.1021/la903246v.

PMID:
20095618
19.

Determination of interspin distance distributions by cw-ESR is a single linear inverse problem.

Chiang YW, Zheng TY, Kao CJ, Horng JC.

Biophys J. 2009 Aug 5;97(3):930-6. doi: 10.1016/j.bpj.2009.05.030.

20.

CBAP interacts with the un-liganded common beta-subunit of the GM-CSF/IL-3/IL-5 receptor and induces apoptosis via mitochondrial dysfunction.

Kao CJ, Chiang YJ, Chen PH, Lin KR, Hwang PI, Yang-Yen HF, Yen JJ.

Oncogene. 2008 Feb 28;27(10):1397-403. Epub 2007 Sep 10.

PMID:
17828305
21.

Hydroxychavicol, a novel betel leaf component, inhibits platelet aggregation by suppression of cyclooxygenase, thromboxane production and calcium mobilization.

Chang MC, Uang BJ, Tsai CY, Wu HL, Lin BR, Lee CS, Chen YJ, Chang CH, Tsai YL, Kao CJ, Jeng JH.

Br J Pharmacol. 2007 Sep;152(1):73-82. Epub 2007 Jul 16.

22.

The isolation of Cryptococcus neoformans from pigeon nests; with remarks on the identification of virulent cryptococci.

KAO CJ, SCHWARZ J.

Am J Clin Pathol. 1957 Jun;27(6):652-63. No abstract available.

PMID:
13444219
23.

Heat resistance of seven strains of Histoplasma.

KAO CJ, SCHWARZ J.

J Infect Dis. 1956 Nov-Dec;99(3):219-21. No abstract available.

PMID:
13376917

Supplemental Content

Support Center